ArticleEClinicalMedicine2026

Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study.

Fei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.